Karayama and colleagues found that increased GNRI, which was calculated from body weight and serum albumin, was associated with better PFS and OS in patients with NSCLC who received nivolumab, regardless of tumor PD‐L1 expression or ECOG‐PS. The gene discussed is ALB; the disease is neoplasm.